6C1 Stock Overview
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
CytomX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.65 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.38 |
| Beta | 1.34 |
| 1 Month Change | 36.66% |
| 3 Month Change | -17.07% |
| 1 Year Change | -83.71% |
| 3 Year Change | -57.03% |
| 5 Year Change | -95.06% |
| Change since IPO | -93.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6C1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.3% | 1.2% | 2.5% |
| 1Y | -83.7% | -14.9% | 14.4% |
Return vs Industry: 6C1 underperformed the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: 6C1 underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| 6C1 volatility | |
|---|---|
| 6C1 Average Weekly Movement | 20.1% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 6C1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6C1's weekly volatility has increased from 15% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 120 | Sean McCarthy | www.cytomx.com |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
CytomX Therapeutics, Inc. Fundamentals Summary
| 6C1 fundamental statistics | |
|---|---|
| Market cap | €56.82m |
| Earnings (TTM) | €28.19m |
| Revenue (TTM) | €122.15m |
2.0x
P/E Ratio0.5x
P/S RatioIs 6C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6C1 income statement (TTM) | |
|---|---|
| Revenue | US$138.10m |
| Cost of Revenue | US$0 |
| Gross Profit | US$138.10m |
| Other Expenses | US$106.23m |
| Earnings | US$31.87m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.40 |
| Gross Margin | 100.00% |
| Net Profit Margin | 23.08% |
| Debt/Equity Ratio | 0% |
How did 6C1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 22:29 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CytomX Therapeutics, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Ying Huang | BofA Global Research |
| Varun Kumar | Cantor Fitzgerald & Co. |